The International Society for the Advancement of Spine Surgery continues to support the adoption of minimally invasive sacroiliac joint fusion by clinicians and payers, limited to procedures using a lateral transiliac approach.
ISASS' updated policy said the "most high-level clinical evidence supporting the safety, effectiveness, durability and economic benefit of lateral MIS [sacroiliac joint fusion] is derived from use of iFuse," according to an article in the December issue of the International Journal of Spine Surgery.
The society did not recommend MIS posterior sacroiliac joint fusion due to the lack of clinical evidence supporting its safety and efficacy.
ISASS also cited key differences from lateral transiliac procedures such as SI-Bone's iFuse procedure that include surgical steps, work effort and anatomy.
The policy provides key "updates on the clinical evidence and the current medical practice including MIS sacroiliac joint fusion treatment options, which have evolved significantly over the past several years," W. Carlton Reckling, MD, SI-Bone CMO and vice president of medical affairs, said in a Jan. 4 news release.
Dr. Reckling said the policy offers a roadmap for clinicians, payers and other evaluators for the adoption of iFuse, which has been used in almost 50,000 cases in the last decade, according to the company.